Importantly, the frequent molecular dysregulation of KAT6A and KAT6B correlates with survival outcomes of cancers, contributing to the exploration of a wide array of small‐molecule inhibitors against KAT6 catalytic activity. The gene discussed is KAT6B; the disease is cancer.